Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 1,609 shares of the firm’s stock in a transaction dated Thursday, August 3rd. The shares were sold at an average price of $197.00, for a total transaction of $316,973.00. Following the completion of the sale, the senior vice president now owns 9,037 shares of the company’s stock, valued at approximately $1,780,289. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Charles Dadswell also recently made the following trade(s):

  • On Monday, July 3rd, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $174.24, for a total transaction of $25,264.80.
  • On Monday, June 5th, Charles Dadswell sold 145 shares of Illumina stock. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75.

Illumina, Inc. (NASDAQ:ILMN) traded up 2.63% during mid-day trading on Monday, reaching $199.58. 938,509 shares of the company’s stock traded hands. The company has a 50-day moving average of $174.66 and a 200-day moving average of $171.89. The company has a market capitalization of $29.14 billion, a price-to-earnings ratio of 40.04 and a beta of 0.83. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The business had revenue of $662 million during the quarter, compared to analyst estimates of $642.38 million. During the same period in the prior year, the business earned $0.86 earnings per share. The business’s quarterly revenue was up 10.3% on a year-over-year basis. Equities research analysts expect that Illumina, Inc. will post $3.65 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was first reported by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally copied and republished in violation of international copyright and trademark law. The original version of this article can be accessed at https://www.dailypolitical.com/2017/08/07/illumina-inc-ilmn-svp-sells-316973-00-in-stock.html.

Hedge funds have recently added to or reduced their stakes in the stock. Penserra Capital Management LLC raised its stake in Illumina by 13.0% in the second quarter. Penserra Capital Management LLC now owns 884 shares of the life sciences company’s stock valued at $153,000 after buying an additional 102 shares in the last quarter. Paradigm Asset Management Co. LLC raised its stake in Illumina by 5.6% in the second quarter. Paradigm Asset Management Co. LLC now owns 950 shares of the life sciences company’s stock valued at $165,000 after buying an additional 50 shares in the last quarter. Meiji Yasuda Asset Management Co Ltd. raised its stake in Illumina by 52.0% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,895 shares of the life sciences company’s stock valued at $502,000 after buying an additional 990 shares in the last quarter. American Century Companies Inc. raised its stake in Illumina by 276.9% in the second quarter. American Century Companies Inc. now owns 475,111 shares of the life sciences company’s stock valued at $82,441,000 after buying an additional 349,058 shares in the last quarter. Finally, Sumitomo Mitsui Trust Holdings Inc. raised its stake in Illumina by 2.1% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 414,826 shares of the life sciences company’s stock valued at $71,981,000 after buying an additional 8,570 shares in the last quarter. 93.81% of the stock is owned by institutional investors and hedge funds.

A number of brokerages recently commented on ILMN. Vetr upgraded shares of Illumina from a “buy” rating to a “strong-buy” rating and set a $196.75 price objective for the company in a research report on Monday, April 24th. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a research report on Friday. J P Morgan Chase & Co restated an “overweight” rating and issued a $250.00 price objective on shares of Illumina in a research report on Wednesday, August 2nd. BidaskClub downgraded shares of Illumina from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. Finally, Deutsche Bank AG restated a “hold” rating and issued a $175.00 price objective (up previously from $165.00) on shares of Illumina in a research report on Saturday, April 29th. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have issued a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $176.63.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.